APTAHEM ENTERS INTO AN AGREEMENT WITH YORKVILLE ADVISORS GLOBAL SECURING FINANCING OF UP TO MSEK 20
Aptahem AB (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved in the disease process, today announce its entry into an issuance agreement with YA II PN Ltd, a fund represented by U.S.-based Yorkville Advisors Global (”Yorkville”). Under the terms of the issuance agreement, Yorkville, acting as the investment manager on behalf of one of its investment funds, will purchase convertible notes of Aptahem. The agreement secures financing of up to MSEK 20,